Yaşlılarda kandida özofajiti: Tek merkez deneyimi

Yıl 2021, Cilt: 20 Sayı: 2, 70 - 74, 26.08.2021

Ferit Çelik Alper Uysal Ali Şenkaya Nalan Ünal İlkçe Kurtulmuş Fatih Tekin Ahmet Özütemiz

https://doi.org/10.17941/agd.978470

Öz

Giriş ve Amaç: Kandida özofajiti, özofagus mukozasının fungal enfeksiyonudur. Bu çalışmada amaç; insan immün yetmezlik virüsü negatif yaşlılarda kandida özofajiti ile ilişkili olarak predispozan faktörleri belirlemek ve eşlik eden endoskopi bulgularını sunmaktır. Gereç ve Yöntem: Bu çalışma; herhangi bir nedenle endoskopi yapılıp, kandida özofajiti tanısı koyulan, insan immün yetmezlik virüsü (-), ≥ 65 yaş hastaların retrospektif tek merkezli irdelenmesini içermektedir. Hastaların yaş, cinsiyet, eşlik eden hastalıkları, insan immün yetmezlik virüsü enfeksiyonu varlığı, kullandığı ilaçları, Diabetes Mellitus varlığı, proton pompa inhibitörü kullanımı, örneklemenin nasıl yapıldığı, başvuru semptomları ve endoskopi yapılma nedenleri taranmıştır. Bulgular: Bu çalışmada 65 yaş üstü olup endoskopi yapılan toplam 2462 hastanın 16’sında (%0.65) kandida özofajiti saptanmıştır. Kandida özofajiti saptanan hastaların yaşları 65 ile 88 arasında olup yaş ortalaması 76.75 ± 7.9 yıldır. Hastaların 8’i (%50) kadındır. Hastaların en sık semptom ve endoskopi yapılma nedeni 8 (%50) hastada disfajidir. Hastaların 5’inde (%31.3) Diabetes Mellitus tanısı saptanmıştır. Hastaların ilaç kullanımları incelendiğinde; 6’sının (%37.5) sürekli proton pompa inhibitörü kullandığı, 5’inin (%31.3) son 1 ay içerisinde antibiyotik kullanım öyküsü olduğu anlaşılmıştır. On dört hastadan (%87.5) biyopsi forsepsi ile, 2 hastadan (%12.5) ise fırçalama tekniği ile örnek alınarak tanıya gidilmiştir. Sonuç: Bu çalışma, bildiğimiz kadarıyla ülkemizde geriatrik popülasyonda kandida özofajiti ile ilişkili ilk çalışmadır. Çalışmamızda insan immün yetmezlik virüsü (-), kandida özofajiti olan geriatrik hastaların yaş etkeni yanında kullanılan ilaçların ve komorbiditelerin de risk faktörü olduğu, bu hastalarda semptomların değişkenlik gösterebildiği akılda tutulmalıdır.

Anahtar Kelimeler

Kandida, özofajit, endoskopi, risk faktörleri

Candida esophagitis in elderly patients: A single center experience

Öz

Background and Aim: Candida esophagitis is a fungal infection of the esophageal mucosa. This study aimed to determine the predisposing factors and accompanying endoscopy findings associated with Candida esophagitis in human immunodeficiency virus-negative elderly patients. Materials and Methods: This was a retrospective single center study involving human immunodeficiency virus-negative patients aged ≥65 years old who underwent endoscopy for any reason and were diagnosed with Candida esophagitis. The age, sex, accompanying diseases, presence of human immunodeficiency virus infection, drugs used, presence of Diabetes Mellitus, use of proton pump inhibitor, how the sampling was done, symptoms at presentation, and the reason for performing endoscopy were reviewed. Results: Candida esophagitis was found in 16 (0.65%) out of 2462 patients aged over 65 years who underwent endoscopy. The patients with Candida esophagitis were aged between 65 and 88 years, with an average age of 76.75 ± 7.9 years. Eight (50%) of the patients were female. Dysphagia was the most common symptom and reason for endoscopy in eight (50%) patients. Diabetes Mellitus was diagnosed in five (31.3%) of the patients. When the drug use of the patients was examined, it was reported that six (37.5%) patients were using proton pump inhibitor continuously, and five (31.3%) patients had a history of antibiotic use in the last one month. The diagnosis was made using biopsy forceps in 14 (87.5%) patients and the brushing technique in two (12.5%) patients. Conclusion: To our knowledge, this is the first study investigating Candida esophagitis in the geriatric population in our country. We suggest that drug use and comorbidities, as well as age factor, were risk factors for Candida esophagitis in geriatric human immunodeficiency virus -negative patients, and symptoms may vary in these patients.
, , ,

Anahtar Kelimeler

Candida, esophagitis, endoscopy, risk factors

Kaynakça

• 1. Wilcox CM, Karowe MW. Esophageal infections: etiology, diagnosis and management. Gastroenterologist 1994;2:188-206.
• 2. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis.1998;26:259-72.
• 3. Rosołowski M, Kierzkiewicz M. Etiology, diagnosis and treatment of infectious esophagitis. Prz Gastroenterol 2013;8:333-7.
• 4. Alsomali MI, Arnold MA, Frankel WL, et al. Challengesto "Classic" esophageal candidiasis: Looks are usually deceiving. Am J Clin Pathol 2017;147:33-42.
• 5. Mimidis K, Papadopoulos V, Margaritis V, et al. Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis: are they always present? Int J Clin Pract 2005;59:210-3.
• 6. Karmeli Y, Stalnikowitz R, Eliakim R, Rahav G. Conventional dose of omeprazole alters gastric flora. Dig Dis Sci 1995;40:2070-3.
• 7. Baehr PH, McDonald GB. Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology 1994;106:509-32.
• 8. Simon MR, Houser WL, Smith KA, Long PM. Esophageal candidiasis as a complication of inhaled corticosteroids. Ann Allergy Asthma Immunol 1997;79:333-8.
• 9. Andersen L, Frederiksen H, Appleyard M. Prevalence of esophageal Candida colonization in a Danish population: special reference to esophageal symptoms, benign esophageal disorders, and pulmonary disease. J Infect Dis 1992;165:389-92.
• 10. Takahashi Y, Nagata N, Shimbo T, et al. Long-term trends in esophageal Candidiasis prevalence and associated risk factors with or without HIV infection: Lessons from an endoscopic study of 80,219 patients. PLoS One 2015;10:e0133589.
• 11. Choi JH, Lee CG, Lim YJ, et al. Prevalence and risk factors of esophageal candidiasis in healthy individuals: a single center experience in Korea. Yonsei Med J 2013;54:160-5.
• 12. Beğer T, Yavuzer H. Yaşlılık ve yaşlılık epidemiyolojisi. Klinik Gelişim 2012;25:1-3.
• 13. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010;16:445-52.
• 14. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
• 15. Hoversten P, Otaki F, Katzka DA. Course of esophageal Candidiasis and outcomes of patients at a single center. Clin Gastroenterol Hepatol 2019;17:200-2.
• 16. Takahashi Y, Nagata N, Shimbo T, et al. Upper gastrointestinal symptoms predictive of Candida esophagitis and erosive esophagitis in HIV and non-HIV patients. An endoscopy-based cross-sectional study of 6011 patients. Medicine (Baltimore) 2015;94:e2138.
• 17. Akbaş E. Özofagusun fungal enfeksiyonları; tek merkez deneyimi. Endoskopi Gastrointestinal 2019;27:7-11.
• 18. Mushi MF, Ngeta N, Mirambo MM, Mshana SE. Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study. Afr Health Sci 2018;18:66-71.
• 19. Underwood JA, Williams JW, Keate RF. Clinical findings and risk factors for Candida esophagitis in outpatients. Dis Esophagus 2003;16:66-69.
• 20. Hoversten P, Kamboj AK, Katzka DA. Infections of the esophagus: an update on risk factors, diagnosis, and management. Dis Esophagus 2018;31.
• 21. Kliemann DA, Pasqualotto AC, Falavigna M, et al. Candida esophagitis: species distribution and risk factors for infection. Rev Inst Med Trop Sao Paulo 2008;50:261-3.
• 22. Tamura Y, Araki A, Chiba Y, et al. A case of type 2 diabetes mellitus in an elderly patient with rapid attenuation of insulin secretion that resembled fulminant type 1 DM but with incomplete beta cell damage. Endocr J 2006;53:633-7.